Qiming Venture Partners and Six Team Members Honored on LP CLUB 2025 Annual Rankings
Recognizing outstanding organizations and individuals who have forged ahead with remarkable achievements over the past year, setting new benchmarks for industry development.
Recently, the LP CLUB Rankings · 2025 Annual List results were officially announced. With the theme "Quality Ignites the Future," the LP CLUB Rankings · 2025 Annual List followed a rigorous selection process including institutional questionnaire submissions, qualification reviews, and data verification. The final awards aim to recognize outstanding institutions and individuals who have demonstrated enterprising spirit and remarkable achievements over the past year, setting new benchmarks for industry development and driving high-quality growth across the industrial ecosystem.
Qiming Venture Partners won 2025 Best Early-Stage/VC Investment Firm TOP 40 and 2025 Best Biomedical Investment Firm TOP 20. Duane Kuang, Founding Managing Partner of Qiming Venture Partners, was named to the 2025 Private Equity Industry Pioneer TOP 50. William Hu, Managing Partner of Qiming Venture Partners, was named to the 2025 Private Equity Investment Opinion Leader TOP 50. Alex Zhou, Managing Partner of Qiming Venture Partners, was named to the 2025 AI Investor TOP 30. Kan Chen, Partner and Co-Head of Healthcare Innovation at Qiming Venture Partners, was named to the 2025 Biomedical Investor TOP 30. Yu Jia, Partner and General Manager of RMB Funds at Qiming Venture Partners, was named to the 2025 Private Equity IR Professional of the Year TOP 40. Hu Qi, Executive Director at Qiming Venture Partners, was named to the 2025 Emerging Young Investor TOP 30.
Qiming Venture Partners won
2025 Best Early-Stage/VC Investment Firm TOP 40
2025 Best Biomedical Investment Firm TOP 20
Duane Kuang, Founding Managing Partner of Qiming Venture Partners
won
2025 Private Equity Industry Pioneer TOP 50
William Hu, Managing Partner of Qiming Venture Partners
won
2025 Private Equity Investment Opinion Leader TOP 50
Alex Zhou, Managing Partner of Qiming Venture Partners
won
2025 AI Investor TOP 30
Kan Chen, Partner and Co-Head of Healthcare Innovation at Qiming Venture Partners
won
2025 Biomedical Investor TOP 30
Yu Jia, Partner and General Manager of RMB Funds at Qiming Venture Partners
won
2025 Private Equity IR Professional of the Year TOP 40
Hu Qi, Executive Director at Qiming Venture Partners
won
2025 Emerging Young Investor TOP 30
Selection Criteria
For this year's rankings, LP CLUB optimized its evaluation metrics. For institutional awards, the criteria expanded to cover five dimensions: institutional profile, recent developments, team building, fund operations and management, and representative case studies. The weighting of each dimension was adjusted between the main list and sector-specific sub-lists; for sector-specific awards, the weight of investment case evaluations in the relevant sector was increased to 50% to better highlight standout performance in a single vertical. For individual awards, while continuing to assess past track records, the evaluation also reflects the "authentic self" of nominees — for example, in the IR award selection, factors such as annual business travel frequency, number of roadshows, and changes in communication frequency with LPs are considered. Self-reflections submitted by nominees are also used to understand their professional character and personal ethos.
Source | LP CLUB
Past Highlights
Qiming Honors | Five Qiming Venture Partners Investors Named to ChinaVenture 2025 Investor Rankings
Qiming Honors | Five Qiming Venture Partners Investors Named to Forbes China 2025 Midas List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early and growth-stage companies in Technology and Healthcare Innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), GenScript ProBio (688520.SH), Insilico Medicine (03696.HK), Hoffmann-La Roche, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.